Celyad Oncology SA · EURONEXT:CYAD

Celyad Oncology SA — Celyad — Investor Presentation (July 2017)

33 slides from Celyad Oncology SA's investor presentation, July 2017

  1. Slide 1: Corporate Presentation July 2017

    Bringing Breakthrough Pioneering Therapies to Patients with Life-Threatening Diseases Corporate Presentation July 2017

  2. Slide 2: Disclaimer

    Disclaimer In addition to historical facts or statements of current condition, this presentation contains forward-looking statements, including statements about the potential safety and feasibility of CAR-T cell therapies, which reflect our current expectations and projections about future events, a

  3. Slide 3: Celyad: Company overview

    Celyad: Company overview Focused on the discovery and the development of specialized cell-based therapies to target cancer • Novel and proprietary CAR-T platform targeting treatment of solid and hematological tumors. • Lead candidate, CYAD-01 (CAR-T NKG2D), currently enrolling in Phase I THINK trial

  4. Slide 4: Celyad's immuno-oncology pipeline is promising

    Celyad’s immuno-oncology pipeline is promising 2015 2016 2017 2018 CLINICAL STAGE Autologous platform CYAD-01 (CAR-T NKG2D) SAFETY THINK - Acute Myeloid Leukemia HEMATO CANCER Phase 1 Trial THINK - Multiple Myeloma INDICATIONS THINK - Ovarian cancer THINK - Colorectal cancer THINK - Pancreatic cance

  5. Slide 5: CYAD-01: A unique construct arming T-cells with an NK receptor

    CYAD-01: A unique construct arming T-cells with an NK receptor to target and destroy cancer cells • One natural construct that capitalizes on the two main pillars of the immune system: NK cells and T-cells. • A natural co-stimulating domain: DAP 10 • Same signaling domain as other CAR-T: CD3ζ 5

  6. Slide 6: A single NK cell receptor binding 8 different ligands

    A single NK cell receptor binding 8 different ligands NKG2D can bind to any of eight naturally occurring ligands known to be overexpressed in more than 80% of solid and hematological tumors NKG2D Binding Ligands MICA MICB ULBPs 1-6 NKG2D ligands are expressed by stressed cells during infection, tumo

  7. Slide 7: NKG2D expresses ligands in broad range of cancer indications

    NKG2D expresses ligands in broad range of cancer indications Expression of at least one of NKG2D ligands: • Triple negative breast cancers : 88% • Colorectal cancers : 88% • Ovarian cancers: 68% • Bladder cancers: 78% of the primary tumors and 100% of the metastases • Pancreatic cancers: 86% • NSCLC

  8. Slide 8: CYAD-01: A novel paradigm to CAR-T

    CYAD-01 : A novel paradigm to CAR-T The next frontier of cell therapy Increasing deliverability and safety Less controlled In Vivo Controlled dosing and PK Next Generation CYAD-01 Expansion with potential to reduce adverse events A cell transplant paradigm for serious adverse events and increase Eff

  9. Slide 9: CYAD-01 Modes of action identified from pre-clinical mouse models

    CYAD-01 Modes of action identified from pre-clinical mouse models • Eradication of established tumors by multiple infusions of CYAD-01 with no pre-conditioning chemotherapy • Short term persistence (7-10 days) • Direct target cell killing • Modulation of the local tumor microenvironment • Reduced nu

  10. Slide 10: CYAD-01 Mediate cytotoxicity and cytokine release during challenge with tumor cells

    CYAD-01 Mediate cytotoxicity and cytokine release during challenge with tumor cells Demoulin et al. Future Oncology 2017 10

  11. Slide 11: CYAD-01 Cell activity in vivo against established Panc-1 tumor cells

    CYAD-01 Cell activity in vivo activity against established Panc-1 tumor cells Demoulin et al. Future Oncology 2017 11

  12. Slide 12: In vitro potency of CYAD-01

    In vitro potency of CYAD-01 Cytotoxicity 120 T a r g e t c e ll k illin g ( % ) 100 80 60 40 20 0 Cytotoxicity mediated by CYAD-001 CAR T cells produced under GMP compliant conditions Kinetics of killing of pancreatic tumor cells by CYAD-001 CAR T cells 12

  13. Slide 13: CYAD-01 autologous clinical program includes various studies

    CYAD-01 autologous clinical program includes various studies 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study CM-CS-1 Study Single IV administration of CYAD-01 AML and MM relapsing post standard of care Open-label dose escalation Phase I study THINK Study Multiple IV administrations

  14. Slide 14: CYAD-01: Clinical development plan

    CYAD-01: Clinical development plan THINK: A multinational (EU/US), open-label, dose escalation Phase 1 study to assess the safety and clinical activity of multiple administrations of CAR-T NKG2D CAR-T NKG2D CAR-T NKG2D Phase 1 safety trial THINK Phase 1 trial • 1 administration • 3 administrations •

  15. Slide 15: CYAD-01: Phase I safety trial successfully completed

    CYAD-01: Phase I safety trial successfully completed 2015 2016 • Single administration, dose-escalation Phase I autologous CAR-T NKG2D study in patients with Acute Myeloid Leukemia and Multiple Myeloma CAR-T NKG2D Phase I Safety trial Dana Farber, last patient included in September 2016. ▪ 1 adminis

  16. Slide 16: CYAD-01: THINK trial study design targeting seven refractory cancers

    CYAD-01: THINK trial study design targeting seven refractory cancers Phase I dose escalation segment Phase I dose expansion segment 3 3 3 Bladder Solid tumors TN Breast 3x108 1x109 3x109 Colorectal All solid tumor types Ovarian Recommended dose Pancreatic 3 3 3 Hematological 3x108 1x109 3x109 tumors

  17. Slide 17: CYAD-01: THINK trial (solid arm) promising early results

    CYAD-01: THINK trial (solid arm) promising early results at first dose level Promising early results at first dose level (3x108) • Two metastatic colorectal cancer patients reported as Stable Disease at 3-month follow-up* • Refractory pancreatic patient was in progression at the same time point • No

  18. Slide 18: CYAD-01 autologous clinical program includes various studies

    CYAD-01 autologous clinical program includes various studies 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study CM-CS-1 Study Single IV administration of CYAD-01 AML and MM relapsing post standard of care Open-label dose escalation Phase I study THINK Study Multiple IV administrations

  19. Slide 19: SHRINK study rationale

    SHRINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SHRINK Study Multiple IV administrations of CYAD-01, combined with FOLFOX Potentially resectable liver metastases from colorectal cancer 1. To control the disease progression • During the manufacturing period, i

  20. Slide 20: SHRINK study rationale

    SHRINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SHRINK Study Multiple IV administrations of NKR-2, combined with FOLFOX Potentially resectable liver metastases from colorectal cancer 5. Strategic integration in standard anti-cancer treatment 6. Strategic inte

  21. Slide 21: LINK study rationale

    LINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study LINK Study Multiple hepatic transarterial administrations Unresectable liver metastases from colorectal cancer 1. The hepatic transarterial administration may offer the advantage of lower systemic toxicity and hig

  22. Slide 22: SIBLINK study rationale

    SIBLINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SIBLINK Study Multiple IV administration of SIBLING CYAD-01 AML relapsing post allo-HCT 1. Evaluate the “standard” CAR-T paradigm lymphodepletion Target Product Profile concept 2. Increase of the in vivo NKR-2

  23. Slide 23: SIBLINK study rationale

    SIBLINK study rationale 2016 2017 2018 2019 2020 Open-label dose escalation Phase I study SIBLINK Study Multiple IV administration of SIBLING CYAD-01 AML relapsing post allo-HCT 4. Strategic integration in standard anti-cancer treatment (“enriched” Donor Lymphocyte Infusion) 5. Strategic intention t

  24. Slide 24: 2017 and 2018 clinical milestones

    2017 and 2018 clinical milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 SOLID • Enrollment • Reporting • Reporting • Completion • Reporting • PFS 6- Dose 1 Dose 1 Dose 2 enrollment Dose 3 Month Data Completed Dose 3 • Completion • Enrollment enrollment • Start Expansion Dose 2 Expansion Se

  25. Slide 25: 2017 and 2018 clinical milestones

    2017 and 2018 clinical milestones Q1 2017 Q2 2017 Q3 2017 Q4 2017 H1 2018 H2 2018 Initiate Study Topline Data PFS 6-Month SHRINK Data Initiate Study Topline Data PFS 6-Month LINK Data Initiate Study Topline Data SIBLINK 25

  26. Slide 26: Intellectual Property – Overview

    Intellectual Property – Overview Three patent families covering autologous products pipeline • CYAD-01 (CAR-T NKG2D): two granted US patents, covering chimeric NK cell receptor CAR-Ts • CAR-T B7H6: pending applications in US, Europe, China and Japan on B7-H6 CAR-Ts B7-H6 is a ligand of the NKp30 rec

  27. Slide 27: Intellectual Property – Allogeneic platform

    Intellectual Property – Allogeneic platform One patent family covering allogeneic platform: • Three granted US patents, covering TCR-deficient T cells, methods of producing them, and methods to use them to treat cancer • >10 applications pending in different jurisdictions • Allogeneic patent provide

  28. Slide 28: Financial snapshot

    Financial snapshot Cash Position: • €72 million as of March 31, 2017 • Enabling company’s activities until Q2 2019 Ticker: Nasdaq (CYAD), Euronext Paris & Euronext Brussels (CYAD.BB) 28

  29. Slide 29: Academic partnerships

    Academic partnerships • Institut Curie is a world class research institution focusing on cancer and immunity, and positioning translational science at the heart of its approach • March 2016: Celyad entered into a 3 year collaboration with Institut Curie • CAR-T platform developed by Celyad was inven

  30. Slide 30: Corporate partnerships

    Corporate partnerships • Novartis is a global healthcare company based in Switzerland that provides solutions to address • ONO is a leader in cancer-immunotherapy in Japan the evolving needs of patients worldwide with the first approved checkpoint inhibitors, OPVIDO© • May 2nd, 2017: Celyad grants t

  31. Slide 31: Management team

    Management team 1. Christian Homsy, CEO 2. Patrick Jeanmart, CFO 3. Jean-Pierre Latere, COO 4. Frédéric Lehmann, VP Clinical Development & Medical Affairs 5. David Gilham, VP R&D 6. Georges Rawadi, VP Business Development & IP 1 2 3 7. Philippe Dechamps, Chief Legal Officer 8. Philippe Nobels, Globa

  32. Slide 32: Celyad ADR programme

    Celyad ADR programme Celyad ADRs trade on NASDAQ Benefits of ADRs to US investors • Symbol CYAD • Clear and settle according to US standards. • Cusip 151205000 • Offer the convenience of stock quotes and dividend payments in US dollars. • Ratio 1 ORD:1 ADR • Can be purchased/sold in the same way as

  33. Slide 33: Thank you

    Thank you Contact: investors@celyad.com BELGIUM USA Celyad SA Celyad Inc. Axis Business Park Seaport East Rue Edouard Belin, 2 2 Seaport Lane B-1435 Mont-Saint-Guibert Boston, MA. 02210 +32(0) 10 39 41 00 +1 857-990-6900 www.celyad.com

Celyad — Investor Presentation (July 2017) on 6ix